BALAXI PHARMA | BLUE PEARL TEXSPIN | BALAXI PHARMA/ BLUE PEARL TEXSPIN |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -129.1 | 566.1 | - | View Chart |
P/BV | x | 3.9 | - | - | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
BALAXI PHARMA BLUE PEARL TEXSPIN |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BALAXI PHARMA Mar-23 |
BLUE PEARL TEXSPIN Mar-23 |
BALAXI PHARMA/ BLUE PEARL TEXSPIN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 670 | 36 | 1,887.3% | |
Low | Rs | 490 | 25 | 1,925.5% | |
Sales per share (Unadj.) | Rs | 330.5 | 8.6 | 3,853.2% | |
Earnings per share (Unadj.) | Rs | 45.2 | -0.3 | -16,770.1% | |
Cash flow per share (Unadj.) | Rs | 46.9 | -0.3 | -17,409.3% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 169.5 | -4.5 | -3,799.8% | |
Shares outstanding (eoy) | m | 10.18 | 0.26 | 3,915.4% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.8 | 3.5 | 50.3% | |
Avg P/E ratio | x | 12.8 | -107.6 | -11.9% | |
P/CF ratio (eoy) | x | 12.4 | -107.6 | -11.5% | |
Price / Book Value ratio | x | 3.4 | -6.7 | -51.0% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 5,905 | 8 | 75,686.1% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 290 | 0 | 144,770.0% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 3,364 | 2 | 150,866.8% | |
Other income | Rs m | 26 | 0 | - | |
Total revenues | Rs m | 3,391 | 2 | 152,049.3% | |
Gross profit | Rs m | 574 | 0 | -820,214.3% | |
Depreciation | Rs m | 18 | 0 | - | |
Interest | Rs m | 14 | 0 | - | |
Profit before tax | Rs m | 569 | 0 | -813,171.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 110 | 0 | - | |
Profit after tax | Rs m | 460 | 0 | -656,614.3% | |
Gross profit margin | % | 17.1 | -3.2 | -531.5% | |
Effective tax rate | % | 19.3 | 0 | - | |
Net profit margin | % | 13.7 | -3.2 | -424.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,935 | 2 | 112,506.4% | |
Current liabilities | Rs m | 531 | 3 | 17,084.6% | |
Net working cap to sales | % | 41.7 | -62.4 | -66.8% | |
Current ratio | x | 3.6 | 0.6 | 658.5% | |
Inventory Days | Days | 2 | 35 | 6.0% | |
Debtors Days | Days | 567 | 1,348,184 | 0.0% | |
Net fixed assets | Rs m | 462 | 0 | 200,687.0% | |
Share capital | Rs m | 102 | 3 | 3,977.0% | |
"Free" reserves | Rs m | 1,624 | -4 | -43,656.5% | |
Net worth | Rs m | 1,726 | -1 | -148,778.4% | |
Long term debt | Rs m | 9 | 0 | - | |
Total assets | Rs m | 2,397 | 2 | 123,540.7% | |
Interest coverage | x | 42.3 | 0 | - | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 1.4 | 1.1 | 122.1% | |
Return on assets | % | 19.8 | -3.7 | -535.2% | |
Return on equity | % | 26.6 | 6.2 | 430.3% | |
Return on capital | % | 33.6 | 6.2 | 544.5% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 802 | 0 | - | |
Fx outflow | Rs m | 40 | 0 | - | |
Net fx | Rs m | 763 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 61 | 0 | -13,206.5% | |
From Investments | Rs m | -106 | NA | - | |
From Financial Activity | Rs m | 255 | 1 | 51,026.0% | |
Net Cashflow | Rs m | 210 | 0 | 525,550.0% |
Indian Promoters | % | 66.9 | 0.1 | 51,430.8% | |
Foreign collaborators | % | 0.0 | 19.5 | - | |
Indian inst/Mut Fund | % | 17.2 | 0.0 | 86,150.0% | |
FIIs | % | 17.2 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 33.1 | 80.3 | 41.3% | |
Shareholders | 5,206 | 8,401 | 62.0% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BALAXI PHARMA With: ADANI ENTERPRISES REDINGTON MMTC SIRCA PAINTS INDIA NOVARTIS
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BALAXI PHARMA | E-WHA FOAM (I) | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -1.53% | 0.00% | -0.08% |
1-Month | 7.17% | 0.00% | 0.53% |
1-Year | 12.16% | 19.44% | 50.88% |
3-Year CAGR | -0.62% | 51.78% | 13.33% |
5-Year CAGR | -0.37% | 28.37% | 21.12% |
* Compound Annual Growth Rate
Here are more details on the BALAXI PHARMA share price and the E-WHA FOAM (I) share price.
Moving on to shareholding structures...
The promoters of BALAXI PHARMA hold a 66.9% stake in the company. In case of E-WHA FOAM (I) the stake stands at 19.7%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BALAXI PHARMA and the shareholding pattern of E-WHA FOAM (I).
Finally, a word on dividends...
In the most recent financial year, BALAXI PHARMA paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of 0.0%.
E-WHA FOAM (I) paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of BALAXI PHARMA, and the dividend history of E-WHA FOAM (I).
For a sector overview, read our pharmaceuticals sector report.
Indian share markets continued the momentum as the session progressed and ended the day higher.